[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332215-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332215-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-proteomics-based-plasma-test-for-early-detection-of-multiple-cancers-in-the-general-population","Novel proteomics-based plasma test for early detection of multiple cancers in the general population","","Early detection of cancer is crucial to reduce the global cancer burden, yet effective screening tests for many cancers remain unavailable. This study developed a proteome-based multi-cancer screening test to identify early-stage cancers with high accuracy. Plasma from 440 individuals (healthy and patients with 18 early-stage solid tumours) was analyzed using proximity extension assay. Sex-specific protein panels achieved high diagnostic performance, including localization signatures that identified tissue of origin in most cases. Performance suggests a promising basis for next-generation population screening.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-proteomics-based-plasma-test-for-early-detection-of-multiple-cancers-in-the-general-population/332215/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-proteomics-based-plasma-test-for-early-detection-of-multiple-cancers-in-the-general-population/332215.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the objective of this proteomics-based study?","Question",{"text":63,"@type":64},"To develop a novel proteome-based multi-cancer screening test that detects early-stage cancers with high accuracy. The goal addressed the lack of effective screening tests for many cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were plasma samples analyzed and which proteins were measured?",{"text":68,"@type":64},"Plasma from 440 individuals was analyzed using a proximity extension assay. More than 3000 proteins were measured per sample to support statistical selection of biomarkers.",{"name":70,"@type":61,"acceptedAnswer":71},"What diagnostic performance did the sex-specific panels show?",{"text":72,"@type":64},"Sex-specific panels using 10 proteins produced high accuracy in both males and females, with high AUC values reported. At stage I and 99% specificity, the panels identified a high proportion of early cancers in each sex group.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332215,1790449664,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Open access Original research  \nTo cite: Budnik B, Amirkhani H, Forouzanfar MH, et al. Novel proteomics-based plasma test for early detection of multiple cancers in the general population. BMJ Oncology 2024;3:e000073 . doi:10 . 1136/ bmjonc-2023-000073  \nReceived 13 April 2023 Accepted 17 October 2023  \n► [http://dx.doi.org/10.1136/](http://dx.doi.org/10.1136/)[ ](http://dx.doi.org/10.1136/)bmjonc-2023-000184  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nNovelna Inc, Palo Alto, California, USA  \nCorrespondence to  \nDr Ashkan Afshin; ashkan@novelna.com and Dr Bogdan Budnik; [bbudnik@novelna.com](bbudnik@novelna.com)  \nNovel proteomics-based plasma test for early detection of multiple cancers in the general population  \nBogdan Budnik, Hossein Amirkhani, Mohammad H Forouzanfar, Ashkan Afshin   \nABSTRACT  \nObjective Early detection of cancer is crucial for reducing the global burden of cancer, but effective screening tests for many cancers do not exist. This study aimed to develop a novel proteome-based multi-cancer screening test that can detect early-stage cancers with high accuracy. Methods and analysis We collected plasma samples from 440 individuals, healthy and diagnosed with 18 earlystage solid tumours. Using proximity extension assay, we measured more than 3000 high-abundance and lowabundance proteins in each sample. Then, using a multistep statistical approach, we identified a limited set of sex-specific proteins that could detect early-stage cancersand their tissue of origin with high accuracy.  \nResults Our sex-specific cancer detection panels consisting of 10 proteins showed high accuracy for both males (area under the curve (AUC): 0.98, 95% CI 0.96, 1) and females (AUC: 0 .983, 95% CI 0 .95, 1 .00) . At stage I and at the specificity of 99%, our panels were able to identify 93%(95% CI 79%, 100%) of cancers among males and 84%(95% CI 68%, 100%) of cancers among females. Our sex-specific localisation panels consisted of 150 proteins and were able to identify the tissue of origin of most cancers in more than 80% of cases. The analysis of the plasma concentrations of proteins selected showed that almost all the proteins were in the low-concentration part of the human plasma proteome.  \nConclusion The proteome-based screening test showed promising performance compared with other technologies and could be a starting point for developing a new generation of screening tests for the early detection of cancer.  \nINTRODUCTION  \nCancer is a leading cause of mortality globally, accounting for one in every six deaths.1 In the absence of established risk factors for many cancers, early detection and early treatment remain the cornerstone of clinical and public health strategies for reducing the global burden of cancer and saving lives. However, currently, no effective test exists for the early detection of many cancers. Nearly 60% of cancer-related deaths are due to cancers for which no screening test exists.2 Additionally, existing screening tests (ie, colonoscopy, CT scan, mammography, pap test) have major  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ Early detection of cancer can enhance patient outcomes significantly. Recent efforts to achieve this have primarily focused on imaging techniques and liquid biopsy approaches such as circulating tumour DNA testing. Proteomics, the large-scale study of proteins, represents a potential avenue for early cancer detection. However, the use of plasma proteins as biomarkers for early cancer detection has been challenging due to the complexity of the proteome and the lack of sensitivity in detecting lowabundance proteins.\u003Cbr>WHAT THIS STUDY ADDS |\n| ⇒ This study demonstrates the potential utility of a plasma proteome-based test for the early detection of 18 solid tumours, representing all major human organs of origin. We found that a limited set of plasma proteins could differentiate ","cbCaioBnabdp1beq","https://ap.wps.com/l/cbCaioBnabdp1beq","pdf",4655557,11,"English","# Abstract\n## Objective\n## Methods and analysis\n## Results\n## Conclusion\n# Introduction\n## Cancer burden and unmet screening needs\n## Limitations of existing approaches\n## Liquid biopsy and genomics-based tests","[{\"question\":\"What was the objective of this proteomics-based study?\",\"answer\":\"To develop a novel proteome-based multi-cancer screening test that detects early-stage cancers with high accuracy. The goal addressed the lack of effective screening tests for many cancers.\"},{\"question\":\"How were plasma samples analyzed and which proteins were measured?\",\"answer\":\"Plasma from 440 individuals was analyzed using a proximity extension assay. More than 3000 proteins were measured per sample to support statistical selection of biomarkers.\"},{\"question\":\"What diagnostic performance did the sex-specific panels show?\",\"answer\":\"Sex-specific panels using 10 proteins produced high accuracy in both males and females, with high AUC values reported. At stage I and 99% specificity, the panels identified a high proportion of early cancers in each sex group.\"}]","Novel proteomics-based plasma test for early detection of multiple cancers in the general population | PDF",1789997363,28]